Rigel Pharmaceuticals | RIGL - Cash And Equivalent


Rigel Pharmaceuticals reported $48.53M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 35M 32M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Celldex Therapeutics USD 35.73M 6.86M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026